The University of Cambridge Department of Haematology is located at the Cambridge Biomedical Campus and the Wellcome Trust Genome Campus. It has laboratories in the Jeffrey Cheah Biomedical Centre, the Cambridge Institute for Medical Research, NHS Blood and Transplant Blood Centre and the Wellcome Sanger Institute. The Head of Department is Professor Brian Huntly.
The department has four main goals:
- To conduct internationally competitive biomedical research.
- To provide education in medical aspects of haematology to undergraduate scientists and medical students.
- To provide postgraduate education, largely through the provision of PhD students.
- To contribute to the clinical activities of the Addenbrooke's Department of Haematology.
Transcriptional characterization of human megakaryocyte polyploidization and lineage commitment. J Thromb Haemost. 2021 May;19(5):1236-1249.
Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021 Apr 26.
Single-cell multi-omics analysis of the immune response in COVID-19. Nat Med. 2021 Apr 20.
Genetic perturbation of PU.1 binding and chromatin looping at neutrophil enhancers associates with autoimmune disease. Nat Commun. 2021 Apr 16;12(1):2298.
Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program. Am J Hum Genet. 2021 Apr 16:S0002-9297(21)00134-8.
Transfer to the clinic: refining forward programming of hPSCs to megakaryocytes for platelet production in bioreactors. Blood Adv. 2021 Apr 13;5(7):1977-1990.
Reconciling Flux Experiments for Quantitative Modeling of Normal and Malignant Hematopoietic Stem/Progenitor Dynamics. Stem Cell Reports. 2021 Apr 13;16(4):741-753.
Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis. Blood Adv. 2021 Apr 13;5(7):1922-1932.
Genetic manipulation and immortalized culture of ex vivo primary human germinal center B cells. Nat Protoc. 2021 Apr 9.
Hematopoietic Stem Cell Heterogeneity Is Linked to the Initiation and Therapeutic Response of Myeloproliferative Neoplasms. Cell Stem Cell. 2021 Apr 1;28(4):780.
Adaptive Cartesian and torsional restraints for interactive model rebuilding. Acta Crystallogr D Struct Biol. 2021 Apr 1;77(Pt 4):438-446.
Angiotensinogen and the Modulation of Blood Pressure. Front Cardiovasc Med. 2021 Mar 18;8:645123.
Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor. J Thromb Haemost. 2021 Mar;19(3):711-718.
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. J Clin Oncol. 2021 Mar 10;39(8):890-901.
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 Mar 8:JCO2003433.
Integrative Single-Cell RNA-Seq and ATAC-Seq Analysis of Human Developmental Hematopoiesis. Cell Stem Cell. 2021 Mar 4;28(3):472-487.e7.
HectD1 controls hematopoietic stem cell regeneration by coordinating ribosome assembly and protein synthesis. Cell Stem Cell. 2021 Mar 4:S1934-5909(21)00058-8.
The NIHR BioResource is a panel of volunteers, with and without health conditions, who will participate in research studies investigating the links between genes, the environment, health and disease enabling scientific discoveries as well as facilitating translational medicine for the benefit of patients.They donate their DNA via a blood or saliva sample which is used together with other information, such as gender, ethnicity, lifestyle and health information to match them to specific research studies. The NIHR Cambridge Centre is one of 13 centres which make up the NIHR BioResource.
The Cambridge Blood and Stem Cell Biobank is a tissue bank for samples from patients with haematological malignancies and normal individuals, including cord blood. We are also the repository for the UK Myeloproliferative Disorders (MPD) sample bank, and several clinical trials for this group of disorders. The bank has collected over 15,000 blood and bone marrow-derived samples to date from patients with haematological malignancies and approximately 2600 normal individuals, all curated in a bespoke database designed to facilitate research activities. Existing samples and prospective collections are available to researchers working on ethically approved studies in malignant blood disorders and normal blood development, and 4800 samples have been transferred to researchers both in the UK and internationally.